Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

Groundbreaking weight-loss drugs like Ozempic and Wegovy have understandably generated a lot of excitement, bringing hope to ...

Lisa Jarvis In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish ...

This time last year, people were still bickering about whether Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound represented a shortcut to losing weight or a medical breakthrough. But with reams of ...

Pharmacy benefit managers started popping up in the late 1960s as providers of claims processing and administrative services ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.

GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now ...

No one has ever known so much about healthy eating and been less successful at following her own advice.